Abstract:Background Venous thromboembolism (VTE) is a significant cause of morbidity and mortality in patients with lung cancer. Systemic therapies, such as chemotherapy (chemo), are associated with increased risk of VTE. Immune checkpoint inhibitors (ICIs) are a new standard of care for the treatment of lung cancer, but their association with VTE is not fully understood. We evaluated the incidence of VTE and risk factors for patients with advanced non-small cell lung cancer (aNSCLC) treated with first-line ICI-based, chemo-based, or ICI+chemo regimens. Methods This retrospective cohort study used HealthCore Integrated Research Environment - Oncology data, an integrated database of administrative claims, coupled with clinical data from a cancer-care quality program. Patients with first-line treatment of stage IV non-small cell lung cancer from July 2014 to August 2020 were grouped based on three treatment types: ICI-based, chemo-based, or ICI+chemo. Patients with VTE before initiation of systemic treatment were excluded. Newly diagnosed VTE events were identified via inpatient and outpatient diagnosis codes. Cox proportional hazards models were used to investigate the factors associated with VTE risk. Results Among 2299 eligible patients (ICI-based, n=605; chemo-based, n=1092; ICI+chemo, n=602) with a median follow-up of 9.1 months, the VTE incidence rates (95% CI) per 100 person-years were 17.8 (95% CI 16.0 to 19.5) overall, 13.5 (95% CI 10.6 to 16.5) for ICI-based, 18.0 (95% CI 15.5 to 20.5) for chemo-based, and 22.4 (95% CI 20.2 to 24.5) for ICI+chemo. The 6-month cumulative incidence of VTE was 8.1% for ICI-based, 10.9% for chemo-based, and 12.8% for ICI+chemo. Pulmonary embolism was most common, accounting for 63% of the VTE events. After controlling for baseline patient characteristics, the risk of VTE was 26% lower for ICI-based regimens than for chemo-based regimens (HR 0.74, p=0.03). There was no meaningful difference in the risk between ICI+chemo and chemo-based regimens (HR 1.12, p=0.36). Previous radiation and severe obesity (body mass index ≥40) were associated with VTE. Conclusions VTE incidence rate per 100 person-years was common across regimens in patients with aNSCLC, but numerically lower for patients receiving ICI-based regimens compared with those receiving chemo-based and ICI+chemo regimens. VTE is a common complication of lung cancer, and there is a continued need for awareness of VTE as a comorbidity in this population.

The Prognostic Influence of Venous Thromboembolism in Non-Small Cell Lung Cancer: A Meta-Analysis and Systematic Review

Risk Factors and Prognosis Value of Venous Thromboembolism in Patients with Advanced Non-Small Cell Lung Cancer: a Case-Control Study

Driver Genes Associated with the Incidence of Venous Thromboembolism in Patients with Non-Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis

Prevalence and clinical characteristics of venous thromboembolism in patients with lung cancer: a systematic review and meta-analysis

The Long-Term Impact of Postoperative Pulmonary Complications after Video-Assisted Thoracic Surgery Lobectomy for Lung Cancer

Venous thromboembolism in non-small-cell lung cancer patients:Report of 15 cases

Efficacy and Safety of Adjunctive Anticoagulation in Patients with Lung Cancer Without Indication for Anticoagulants: a Systematic Review and Meta-Analysis

Prognostic value of venous thromboembolism in patients with advanced pancreatic cancer: a systematic review and meta-analysis

Clinical Significance And Role Of Lymphatic Vessel Invasion As A Major Prognostic Implication In Non-Small Cell Lung Cancer: A Meta-Analysis

[Retrospective Analysis of Risk Factors for Venous Thromboembolism in 283 Patients with Lung Cancer During Systemic Therapy].

A systematic review of risk prediction model of venous thromboembolism for patients with lung cancer

Establishment and Validation of a Risk Prediction Model for Venous Thromboembolism in Lung Cancer Based on a Meta-Analysis

The Impact of Metastasis Tumour Supressor-1 (mtss1) on the Metastatic Characteristics of Non Small Cell Lung Cancer and Its Association with Smoking History

Diagnosis and Treatment Characteristics of Lung Cancer Patients with Venous Thromboembolism

Prognostic Value of Vascular Endothelial Growth Factor Expression in Patients with Lung Cancer: A Systematic Review with Meta-Analysis

Venous thromboembolism incidence and risk factors associated with immune checkpoint inhibitors among patients with advanced non-small cell lung cancer

Models for predicting venous thromboembolism in ambulatory patients with lung cancer: A systematic review and meta-analysis

Risk Factors and Prediction Models for Venous Thromboembolism in Ambulatory Patients with Lung Cancer

Venous and Arterial Thromboembolism in Lung Cancer Patients: A Retrospective Analysis

Effect and adverse reaction of anticoagulant therapy and its potential influencing factors in patients with lung cancer and venous thromboembolism

The Society for Translational Medicine: the Assessment and Prevention of Venous Thromboembolism after Lung Cancer Surgery